Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
autologous fecal microbiota transplantation (Tel Aviv Sourasky Medical Center)
- Development stage
- Preclinical
- Lead developer
- Seres Therapeutics
- Modality
- Synthetic Biology Platforms → Engineered Microbial Therapeutics → Microbiome Therapeutics, Fresh FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Frozen FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Cell Therapies, Genetically Modified Bacteria → Engineered Microbial Therapeutics → Microbiome Therapeutics, Microbial Metabolites → Microbiome-Derived Products → Microbiome Therapeutics, Microbial Proteins → Microbiome-Derived Products → Microbiome Therapeutics, Complex Communities → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics
- Administration
- Rectal
01
Overview
Autologous fecal microbiota transplantation (aFMT) is an investigational biologic therapy developed and studied by the Tel-Aviv Sourasky Medical Center for the treatment of antibiotic-associated dysbiosis. The procedure involves collecting and preserving a patient's own fecal matter prior to antibiotic treatment. After the antibiotic course is completed, the preserved microbiota is transplanted back to the patient to restore the native gut microbiome. A clinical study (NCT03218579) and a corresponding publication in *Cell* in 2018 demonstrated that aFMT promoted rapid and near-complete reconstitution of the gut mucosal microbiome, whereas comparator treatment with probiotics actually delayed recovery. [9] The intervention is prepared from the patient's own pre-treatment stool and does not have a commercial brand name.
- Other names
- fecal microbiota-Tel-Aviv Sourasky Medical Center-antibiotic-associated dysbiosisaFMTfecal microbiota transplantbacteriotherapy
Beyond the preview
Go deeper on autologous fecal microbiota transplantation (Tel Aviv Sourasky Medical Center).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on autologous fecal microbiota transplantation (Tel Aviv Sourasky Medical Center).